Global Investigational New Drug CDMO Market Growth (Status and Outlook) 2024-2030

Global Investigational New Drug CDMO Market Growth (Status and Outlook) 2024-2030

Investigational New Drug CDMO refers to a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of investigational new drugs (INDs). INDs are drugs that are being tested for their safety and efficacy in clinical trials before they receive regulatory approval for general use. An Investigational New Drug CDMO provides services including formulation development, process optimization, scale-up, and manufacturing of INDs to support the drug development process. These organizations play a crucial role in helping pharmaceutical companies bring new drugs from the research phase through to clinical trials.

The global Investigational New Drug CDMO market size is projected to grow from US$ 4904 million in 2024 to US$ 7254 million in 2030; it is expected to grow at a CAGR of 6.7% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Investigational New Drug CDMO Industry Forecast” looks at past sales and reviews total world Investigational New Drug CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Investigational New Drug CDMO sales for 2023 through 2029. With Investigational New Drug CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Investigational New Drug CDMO industry.

This Insight Report provides a comprehensive analysis of the global Investigational New Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Investigational New Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Investigational New Drug CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Investigational New Drug CDMO and breaks down the forecast by Type, by End User, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Investigational New Drug CDMO.

United States market for Investigational New Drug CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Investigational New Drug CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Investigational New Drug CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Investigational New Drug CDMO players cover Catalent, Inc., Lonza, Recipharm AB, Siegfried Holding AG, Patheon Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Investigational New Drug CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:
Small Molecule
Large Molecule

Segmentation by End User:
Pharmaceutical Companies
Biotech Companies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Small Molecule
Large Molecule

Segmentation by End User:
Pharmaceutical Companies
Biotech Companies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Catalent, Inc.
Lonza
Recipharm AB
Siegfried Holding AG
Patheon Inc.
Covance
IQVIA Holdings Inc.
Cambrex Corporation
Charles River Laboratories International, Inc.
Syneous Health

Please note: The report will take approximately 2 business days to prepare and deliver.